Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability of istaroxime to improve heart function and low blood pressure in the setting of early cardiogenic shock due to heart failure. The Company is looking to extend the positive results on these parameters as observed in the Company's first SEISMiC Phase 2 clinical study that was previously reported. In addition, the Company hopes that the study results will substantiate the encouraging observations from the Company's Phase 2 clinical study, indicating istaroxime has a favorable renal profile and does not increase cardiac arrhythmias. The SEISMiC Extension Study is utilizing longer dosing duration and tapering the dosing to assess the potential benefits.
Windtree Therapeutics公司("Windtree"或"公司") (納斯達克股票代碼: WINT),一家專注於推進早期和晚期創新治療方案以應對重要疾病的生物技術公司,今天宣佈已成功完成其在早期心源性休克由心力衰竭引起的SEISMiC階段2b期研究對istaroxime的招募。該研究旨在評估istaroxime在早期心力衰竭引起的心原性休克情況下改善心臟功能和低血壓的能力。該公司希望延續此次研究的積極結果,即之前報告的公司首個SEISMiC第2期臨床研究中觀察到的這些參數的積極結果。此外,公司希望該研究結果將證實公司第2期臨床研究中對istaroxime具有有利的腎功能分析,並且不會增加心臟心律失常的鼓舞人心的觀察。SEISMiC延伸研究正在利用更長的給藥時間和減量給藥來評估潛在的好處。